France· FR:67568483
ASPAVELI 1080 mg, solution pour perfusion
A medicinal product containing pegcétacoplan, registered in France by SWEDISH ORPHAN BIOVITRUM (SUEDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PEGCÉTACOPLAN
- Manufacturer
- SWEDISH ORPHAN BIOVITRUM (SUEDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip1334009302436571 flacon(s) en verre de 20 mlEUR 3.3
- cip1334009302436718 flacon(s) en verre de 20 mlEUR 25.5
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pegcétacoplan in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsAspaveli 1080 mg oplossing voor infusieApellis Ireland Limited
- United StatesEmpaveliApellis Pharmaceuticals, Inc.
- CzechiaASPAVELISwedish Orphan Biovitrum AB (publ), Stockholm
- SwitzerlandAspaveli
- FinlandASPAVELISwedish Orphan Biovitrum AB (publ)
- United KingdomAspaveli 1080mg/20ml solution for infusion vialsSwedish Orphan Biovitrum Ltd
- BelgiumAspaveli 1080 mgSwedish Orphan Biovitrum (Publ)
- IcelandASPAVELI*Swedish Orphan Biovitrum AB (publ)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Aspaveli
- Liechtenstein · Aspaveli
- Norway · Aspaveli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2544c6b4-74e9-45e1-b3cd-19092ae6fc81 GET /v1/drugs/2544c6b4-74e9-45e1-b3cd-19092ae6fc81?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67568483",
"date_amm": "2021-12-13",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1595",
"substance": "PEGCÉTACOPLAN",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution pour perfusion",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about pegcétacoplan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.